Continual Cuffless BP Monitoring Can Classify Time-in-Target-Range Accurately
By Elana Gotkine HealthDay Reporter
FRIDAY, July 12, 2024 -- Continual cuffless blood pressure (BP) monitoring can classify time-in-target-range (TTR) accurately, according to a study published online June 26 in Frontiers in Medicine.
Naomi D.L. Fisher, M.D., from Brigham and Women's Hospital in Boston, and colleagues examined the optimal duration and frequency for reliable, practice TTR assessment in clinical settings using continual monitoring in a retrospective study analyzing 2.3 million BP readings from 5,189 individuals using a cuffless BP monitor. Over 15 consecutive days, systolic BP data were assessed and participants were classified into risk-related TTR groups; measurement frequencies and durations were compared to this reference. Two specific configurations paralleling ambulatory ("One-Day-24h") and home ("One-Week-Daytime") BP monitoring were further analyzed.
The researchers found that 63.0, 19.0, and 18.0 percent of the participants were classified as high-, intermediate-, and low-risk, respectively, based on the reference TTR. Compared with the reference TTR, "One-Day-24h" and "One-Week-Daytime" inaccurately classified 26 and 45 percent of participants, respectively. With both schedules, classification accuracy was high for participants with very low or very high reference TTR, but otherwise was poor. Only with seven days of continual 24-hour monitoring was there accuracy of ≥90 percent in TTR classification.
"Our results suggest that continual cuffless BP monitoring enables rapid and practical assessment of systolic BP TTR, an emerging metric of hypertension control," the authors write.
Several authors disclosed ties to medical device companies, including Aktiia, which manufactures the cuffless device used in the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2024
Read this next
PREVENT Equations Show Lower ASCVD Risk Than Pooled Cohort Equations
MONDAY, July 15, 2024 -- The 10-year predicted atherosclerotic cardiovascular disease (ASCVD) risk estimated by the Predicting Risk of cardiovascular disease EVENTs (PREVENT)...
Successful Pregnancy Possible for Stem Cell Transplant Recipients
MONDAY, July 15, 2024 -- Successful pregnancies are feasible for female allogeneic hematopoietic cell transplant (alloHCT) recipients, with most pregnancies occurring...
Out-of-Pocket Costs Considerable, Increasing for Prostate Cancer Diagnostic Testing
MONDAY, July 15, 2024 -- For patients with private insurance undergoing diagnostic testing after prostate-specific antigen (PSA)-based screening, out-of-pocket costs are...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.